| 查看: 491 | 回复: 0 | ||
caijing1986铜虫 (初入文坛)
|
[求助]
专业翻译英文摘要
|
|
Standard Versus Extended Duration DirectActing Antiviral Therapy in Hepatitis C Patients With Slow Response to Treatment Abstract Background: Response-guided hepatitis C therapy was standard with interferon-based regimens but is not used for direct-acting antivirals (DAAs). Week 4 viral kinetics may predict sustained virological response (SVR) with DAAs, but it is unclear whether extending therapy in slow responders affects outcomes. Objectives: The primary objective was to compare SVR rates between traditional and extended duration groups. Secondary objectives were to compare SVR rates among subgroups and to determine factors associated with SVR. Methods: This institutional review board–approved, retrospective, single-center study identified patients with chronic hepatitis C virus (HCV) infection with detectable week 4 HCV RNA who were treated with DAAs. Patients were excluded for early discontinuation, treatment regimen not recommended first-line, or missing HCV RNA labs. Patients were stratified into traditional and extended duration groups. The primary end point was SVR. Secondary end points included factors associated with SVR and rationale for extension of therapy duration. Results: A total of 363 patients were included; 58 (16%) received extended therapy. Patients were primarily genotype 1a (70%) and treatment naïve (80%). More than half had advanced fibrosis or cirrhosis. SVR12 rates were 100% in the extended duration group and 96.7% in the traditional duration group (P = 0.37). There were no associations with SVR and prespecified patient-specific factors. Sample size was limited. Conclusion and Relevance:Based on these findings, a recommendation for extension of therapy cannot be made for patients with detectable HCV RNA at week 4 of treatment at this time. Cost analyses may help guide recommendations to re-treat rare failures versus extend therapy in all slow responders. Keywords hepatitis C, response-guided therapy, direct-acting antivirals |
回复此楼» 猜你喜欢
with editor 两个月了，什么原因？
已经有16人回复
-
普通院校药学硕士，做合成的，感觉找不到工作
已经有17人回复
-
如何分离原料与产品
已经有13人回复
-
LWT投
已经有3人回复
-
真的好想读博！
已经有22人回复
-
博士白读了
已经有49人回复
-
基金开始函评了吗？
已经有16人回复
-
没学上
已经有12人回复
-
研二光催化6月底四篇二区什么水平
已经有15人回复
-
环肽的合成
已经有5人回复
5